India, Aug. 3 -- Medicus Pharma Ltd. (MDCX) on Monday announced the appointment of Faisal Mehmud as Chief Executive Officer (CEO) of its U.K. subsidiary, Antev Limited, effective August 30, 2026.
Mehmud will continue to serve as Chief Medical Officer (CMO) of Medicus and Co-Chairman of Antev, providing unified scientific, clinical, regulatory and operational leadership as the company advances the development of Teverelix for advanced prostate cancer, acute urinary retention and women's health indications.
Mehmud succeeds Amit Kohli, who has served as interim CEO of Antev since Medicus completed its acquisition of the company in August 2025.
Mehmud brings more than 20 years of global biopharmaceutical leadership experience and has previou...